Literature DB >> 17526930

Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report.

E Collantes1, P Zarco, E Muñoz, X Juanola, J Mulero, J L Fernández-Sueiro, J C Torre-Alonso, J Gratacós, C González, E Batlle, P Fernández, L F Linares, E Brito, L Carmona.   

Abstract

OBJECTIVE: The national registry of <span class="Disease">spondyloarthropathies (REGISPONSER) is launched to classify patients with this group of diseases treated in Spanish rheumatology clinics. This manuscript describes the methodological and organizational background as well as characteristics of patients finally included, and provides a comparative analysis between characteristics of both ankylosing spondylitis and undifferentiated spondyloarthropathy groups of patients. PATIENTS AND METHODS: Twelve members of the GRESSER group have participated in the registry, for a one-year recruitment period. All consecutively registered adult patients treated in their clinics met the classification criteria of the European Spondyloarthropathies Study Group (ESSG). Data collected reflect the socio-demographic characteristics, as well as disease activity and functional status, clinical form at onset, treatment used and quality of life; all measured by standard instruments.
RESULTS: Throughout 1 yr, 1385 patients have been included in the registry: 939 males (68%) and 440 females (32%), with an average age of 47 +/- 13 years (mean +/- s.d.), and an average disease duration of 12 +/- 9 years. Diagnoses of the included patients were: AS (n = 842, 61%), PsA (n = 290, 21%), u-SpA (n = 205, 15%), reactive arthritis (n = 16, 1.2%), inflammatory bowel disease arthritis (n = 13, 0.9%) and JCA-spondyloathropathy (n = 13, 0.9%). Regarding clinical form, 54% had axial disease, 20% peripheral disease, 24% mixed disease and 0.6% isolated enthesitic form. Low-back pain was the first symptom reported in 53% of the patients, and most common extra-articular disease manifestations were psoriasis (25%), anterior uveitis (16%) and intestinal inflammatory disease (4%). Some kind of work disability was reported by 353 patients (25.5%).
CONCLUSIONS: Such databases are very useful to obtain information about characteristics of SpA patients treated in a certain location or following a specific treatment practice, and provide a tool for assessing the impact of the disease. Data collected in this registry provide an appropriate clinical and demographic profile of patients suffering from SpA in Spain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526930     DOI: 10.1093/rheumatology/kem084

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  39 in total

1.  Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts.

Authors:  Fernando M Pimentel-Santos; Ana Filipa Mourão; Célia Ribeiro; José Costa; Helena Santos; Anabela Barcelos; Patricia Pinto; Fátima Godinho; Margarida Cruz; Elsa Vieira-Sousa; Rui André Santos; Sara Rabiais; Jorge Félix; João Eurico Fonseca; Henrique Guedes-Pinto; Matthew A Brown; Jaime C Branco
Journal:  Clin Rheumatol       Date:  2011-10-19       Impact factor: 2.980

2.  Evaluating the reliability of Persian version of ankylosing spondylitis quality of life (ASQoL) questionnaire and related clinical and demographic parameters in patients with ankylosing spondylitis.

Authors:  Sasan Fallahi; Ahmad Reza Jamshidi; Katayoon Bidad; Mostafa Qorbani; Mahdi Mahmoudi
Journal:  Rheumatol Int       Date:  2013-10-30       Impact factor: 2.631

3.  Nonradiographic axial spondyloarthritis. What brings the new concept?

Authors:  E Collantes-Estevez; Luis R Espinoza; Luis R Espinosa
Journal:  Clin Rheumatol       Date:  2014-10-21       Impact factor: 2.980

4.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; A Heiligenhaus; U Pleyer; W-H Böhncke; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

5.  Magnetic resonance imaging assessment in patients with axial spondyloarthritis: development of checklists for use in clinical practice.

Authors:  Raquel Almodóvar; Ángel Bueno; Enrique Batlle; Emma Beltrán-Catalán; Daniel Bernabeu; Carmen Castro Copete; Angela Cepero; Concha Crespo; Fernando Díez; Cristina Fernández-Carballido; Fran García Lorente; Angel Gil De Miguel; Xavier Juanola; Luis Linares; Rafael Montero Pérez-Barquero; Carmen Castro; Manuel José Moreno Ramos; Mireia Moreno; Victoria Navarro-Compán; Christopher Pack; Carlos Quiles; Maite Veintemillas; Pedro Zarco
Journal:  Rheumatol Int       Date:  2019-09-18       Impact factor: 2.631

Review 6.  The incidence of sexually acquired reactive arthritis: a systematic literature review.

Authors:  Hayley J Denison; Elizabeth M Curtis; Michael A Clynes; Collette Bromhead; Elaine M Dennison; Rebecca Grainger
Journal:  Clin Rheumatol       Date:  2016-08-01       Impact factor: 2.980

7.  Candidate's single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis.

Authors:  Ruxandra Schiotis; Alejandra Sánchez; Alejandro Escudero; Nerea Bartolomé; Magdalena Szczypiorska; Pilar Font; Antonio Martínez; Diego Tejedor; Marta Artieda; Juan Mulero; Anca Buzoianu; Eduardo Collantes-Estévez
Journal:  Rheumatol Int       Date:  2013-12-15       Impact factor: 2.631

8.  Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis.

Authors:  Mi Ryoung Seo; Hae Lim Baek; Hyun Hwa Yoon; Hee Jung Ryu; Hyo-Jin Choi; Han Joo Baek; Kwang-Pil Ko
Journal:  Clin Rheumatol       Date:  2014-09-05       Impact factor: 2.980

9.  Color Doppler and spectral Doppler ultrasound detection of active sacroiliitis in spondyloarthritis compared to physical examination as gold standard.

Authors:  Concepción Castillo-Gallego; Eugenio De Miguel; Miriam García-Arias; Chamaida Plasencia; Leticia Lojo-Oliveira; Emilio Martín-Mola
Journal:  Rheumatol Int       Date:  2017-09-13       Impact factor: 2.631

10.  Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.

Authors:  Martin Rudwaleit; Pascal Claudepierre; Martina Kron; Sonja Kary; Robert Wong; Hartmut Kupper
Journal:  Arthritis Res Ther       Date:  2010-03-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.